Evidence map›Paper›PMID 31705172›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2020

Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma.

Cristina Ferrone, Lipika Goyal, Motaz Qadan, Debra Gervais, Dushyant V Sahani, Andrew X Zhu, Theodore S Hong, Lawrence S Blaszkowsky, Kenneth K Tanabe, Mark Vangel and 17 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06265272 (Technical Development and Clinical Validation of a Comprehensive One-stop Shop Assessment of the Cirrhotic Liver With [68Ga]Ga-PSMA-11 PET/MRI), which is not on this map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06265272 recruitingnot on this mapstarted 2023, after this paper: background citation

Technical Development and Clinical Validation of a Comprehensive One-stop Shop Assessment of the Cirrhotic Liver With [68Ga]Ga-PSMA-11 PET/MRI

TypeobservationalSponsorMassachusetts General HospitalRan2023 to 2026Enrolled45ConditionsLiver Cirrhosis, Hepatic Cell Carcinoma, Portal HypertensionArmsInjection of a gadolinium contrast agen, Radiotracer Injection, Imaging
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Diagnostic performance of whole-body [European radiology · 2024
    Pooled it
  2. Present and future of liver transplantation for cholangiocellular carcinoma: moving toward personalized multiparametric transplantability patterns.Transplant international : official journal of the European Society for Organ Transplantation · 2026
    Review
  3. Review
  4. Comparison ofAbdominal radiology (New York) · 2023
    Article
  5. Article
  6. Review
  7. The focus clinical research in intrahepatic cholangiocarcinoma.European journal of medical research · 2022
    Review
  8. Review
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Improving staging of rectal cancer in the pelvis: the role of PET/MRI.European journal of nuclear medicine and molecular imaging · 2021
    Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 7 countries.

Cristina FerroneDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Lipika GoyalDepartment of Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Motaz QadanDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Debra GervaisDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School, WHT 270, 55 Fruit St., Boston, MA, 02114, USA.
Dushyant V SahaniDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School, WHT 270, 55 Fruit St., Boston, MA, 02114, USA.
Andrew X ZhuDepartment of Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Theodore S HongDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Lawrence S BlaszkowskyDepartment of Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Kenneth K TanabeDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Mark VangelDepartment of Biostatics, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Barbara J AmorimDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School, WHT 270, 55 Fruit St., Boston, MA, 02114, USA.
Jennifer Y WoDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Umar MahmoodDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School, WHT 270, 55 Fruit St., Boston, MA, 02114, USA.
Pari V PandharipandeDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School, WHT 270, 55 Fruit St., Boston, MA, 02114, USA.
Ciprian CatanaMartinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, 149 13th, Charlestown, MA, 02129, USA.
Virginia P DuenasDepartment of Nuclear Medicine and Radiology, Hospital HM Puerta del Sur, Avda Carlos V 70, 28938, Madrid, Spain.
Yolanda Q CollazoDepartment of Surgery, Hospital HM Sanchinarro, Avda Carlos V 70, 28938, Madrid, Spain.
Lina G CanamaqueDepartment of Nuclear Medicine and Radiology, Hospital HM Puerta del Sur, Avda Carlos V 70, 28938, Madrid, Spain.
Liran DomachevskyDepartment of Radiology and Nuclear Medicine, Assuta Medical Center, HaBarzel St. 20, Tel Aviv-Yafo, Israel.
Hanna H BernstineDepartment of Radiology and Nuclear Medicine, Assuta Medical Center, HaBarzel St. 20, Tel Aviv-Yafo, Israel.
David GrosharDepartment of Radiology and Nuclear Medicine, Assuta Medical Center, HaBarzel St. 20, Tel Aviv-Yafo, Israel.
Tiffany Tsing-Fang ShihDepartment of Medical Imaging and Radiology, National Taiwan University College of Medicine and Hospital, No. 7, Chung-Shan South Rd., Taipei, 10016, Taiwan.
Yan LiDepartment of Radiology, Universitatsklinikum, Essen University, Hufelandstraße 55, 45147, Essen, Germany.
Ken HerrmannDepartment of Nuclear Medicine, Universitatsklinikum, Essen University, Hufelandstraße 55, 45147, Essen, Germany.
Lale UmutluDepartment of Radiology, Universitatsklinikum, Essen University, Hufelandstraße 55, 45147, Essen, Germany.
Bruce R RosenMartinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, 149 13th, Charlestown, MA, 02129, USA.
Onofrio A CatalanoDepartment of Radiology, Massachusetts General Hospital, Harvard Medical School, WHT 270, 55 Fruit St., Boston, MA, 02114, USA. onofriocatalano@yahoo.it.ORCID 0000-0001-7733-4138
Harvard University · USAssuta Medical Center · ILEssen University Hospital · DEUniversity Hospital HM Puerta del Sur · ESHospital Universitario HM Sanchinarro · ESNational Taiwan University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIntrahepatic cholangiocarcinoma (ICC) is associated with a poor prognosis with surgical resection offering the best chance for long-term survival and potential cure. However, in up to 36% of patients who undergo surgery, more extensive disease is found at time of operation requiring cancellation of surgery. PET/MR is a novel hybrid technology that might improve local and whole-body staging in ICC patients, potentially influencing clinical management. This study was aimed to investigate the possible management implications of PET/MR, relative to conventional imaging, in patients affected by untreated intrahepatic cholangiocarcinoma.

methodsRetrospective review of the clinicopathologic features of 37 patients with iCCC, who underwent PET/MR between September 2015 and August 2018, was performed to investigate the management implications that PET/MR had exerted on the affected patients, relative to conventional imaging.

resultsOf the 37 patients enrolled, median age 63.5 years, 20 (54%) were female. The same day PET/CT was performed in 26 patients. All patients were iCCC-treatment-naïve. Conventional imaging obtained as part of routine clinical care demonstrated early-stage resectable disease for 15 patients and advanced stage disease beyond the scope of surgical resection for 22. PET/MR modified the clinical management of 11/37 (29.7%) patients: for 5 patients (13.5%), the operation was cancelled due to identification of additional disease, while 4 "inoperable" patients (10.8%) underwent an operation. An additional 2 patients (5.4%) had a significant change in their operative plan based on PET/MR.

conclusionsWhen compared with standard imaging, PET/MR significantly influenced the treatment plan in 29.7% of patients with iCCC.

trial registration2018P001334.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaFemaleFluorodeoxyglucose F18HumansMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMaleMiddle AgedNeoplasm StagingPositron-Emission TomographyPositron Emission Tomography Computed TomographyRadiopharmaceuticalsRetrospective StudiesFluorodeoxyglucose F18RadiopharmaceuticalsCholangiocarcinomaClinical managementPET/MRStaging

Identifiers

PMID31705172
OpenAlexW2986435756

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.